Clinical Trials › NCT04742400
Active, Not RecruitingPhase 2
Tolebrutinib, a Brain-penetrant Bruton's Tyrosine Kinase Inhibitor, for the Modulation of Chronically Inflamed White Matter Lesions in Multiple Sclerosis
Sponsored by National Institute of Neurological Disorders and Stroke (NINDS)
Interested in joining? Eligibility criteria and contact info are on ClinicalTrials.gov.
View on ClinicalTrials.gov 12
Target enrollment
1
U.S. states
Apr 2021
Start date
Dec 2025
Expected completion
Interventions / Treatments
tolebrutinib 60mgtolebrutinib 120mg
Conditions studied
Multiple Sclerosis
Where this trial is running (1 site)
Maryland1 site
Bethesda
MS centers in Maryland
Compare treatment centers near a trial site by center type, providers and trials.
View Maryland centersMore Phase 2 trials
Browse all Phase 2 MS trialsThe app
Check out the MS Buddy app
Track symptoms, monitor wellness, and stay on top of your MS care. It’s free, with no ads. Built by people living with MS.